Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Otsuka Pharmaceutical Development & Commercialization, Inc.
With
H. Lundbeck A/S
The introduction of atypical antipsychotics has created a renewed interest in adjunctive therapy for MDD, particularly for treatment-resistant MDD. Several atypical antipsychotics have been shown to enhance the response to ADT. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled, fixed-dose trial designed to assess the safety and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy to an assigned open-label ADT in depressed subjects with and without anxious distress.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and Female subjects between 18-65 years of age, with diagnosis of major depressive disorder with or without anxious distress
Current depressive episode must be at least 8 weeks in duration
You may not be if
Subjects with a history of Neuroleptic Malignant Syndrome or Serotonin Syndrome
Subjects who report an inadequate response to more than 3 antidepressant treatments in the current episode
Subjects with a current Axis I diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder